← Back to Screener
EVOGENE LTD. (EVGN)
Price$0.80
Favorite Metrics
Price vs S&P 500 (26W)-45.49%
Price vs S&P 500 (4W)-5.09%
Market Capitalization$10.34M
All Metrics
Book Value / Share (Quarterly)$0.13
P/TBV (Annual)2.09x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)31.88%
Cash Flow / Share (Quarterly)$-1.56
Price vs S&P 500 (YTD)-25.00%
Gross Margin (TTM)49.04%
Net Profit Margin (TTM)-214.59%
EPS (TTM)$-1.16
10-Day Avg Trading Volume0.06M
EPS Excl Extra (TTM)$-1.16
Revenue Growth (5Y)29.94%
EPS (Annual)$-1.08
ROI (Annual)-101.36%
Gross Margin (Annual)50.32%
Net Profit Margin (5Y Avg)-1082.24%
Cash / Share (Quarterly)$1.49
Revenue Growth QoQ (YoY)-80.51%
ROA (Last FY)-42.33%
Revenue Growth TTM (YoY)-53.54%
EBITD / Share (TTM)$-1.64
ROE (5Y Avg)-86.46%
Operating Margin (TTM)-354.00%
Cash Flow / Share (Annual)$-1.56
P/B Ratio9.05x
P/B Ratio (Quarterly)8.71x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)-0.11x
Net Interest Coverage (TTM)-11.14x
ROA (TTM)-29.68%
EV / EBITDA (TTM)-1.17x
EPS Incl Extra (Annual)$-1.08
Current Ratio (Annual)4.54x
Quick Ratio (Quarterly)4.48x
3-Month Avg Trading Volume0.35M
52-Week Price Return-18.66%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.13
P/S Ratio (Annual)2.68x
Asset Turnover (Annual)0.19x
52-Week High$2.42
Operating Margin (5Y Avg)-1237.61%
EPS Excl Extra (Annual)$-1.08
CapEx CAGR (5Y)-27.63%
Tangible BV CAGR (5Y)-35.61%
26-Week Price Return-41.50%
Quick Ratio (Annual)4.48x
13-Week Price Return-20.92%
Total Debt / Equity (Annual)0.95x
Current Ratio (Quarterly)4.54x
Enterprise Value$-0.42
Revenue / Share Growth (5Y)67.69%
Asset Turnover (TTM)0.14x
Book Value / Share Growth (5Y)4.18%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)1.89x
Pretax Margin (Annual)-350.32%
Cash / Share (Annual)$1.49
3-Month Return Std Dev63.13%
Gross Margin (5Y Avg)-166.84%
Net Income / Employee (TTM)$-0
ROE (Last FY)-198.12%
Net Interest Coverage (Annual)-16.49x
EPS Basic Excl Extra (Annual)$-1.08
P/FCF (TTM)8.69x
Receivables Turnover (TTM)5.62x
Total Debt / Equity (Quarterly)2.21x
EPS Incl Extra (TTM)$-1.16
Receivables Turnover (Annual)5.47x
ROI (TTM)105.79%
P/S Ratio (TTM)2.61x
Pretax Margin (5Y Avg)-1205.59%
Revenue / Share (Annual)$0.49
Tangible BV / Share (Annual)$0.33
Price vs S&P 500 (52W)-48.49%
Year-to-Date Return-22.35%
5-Day Price Return4.15%
EPS Normalized (Annual)$-1.08
ROA (5Y Avg)-42.86%
Net Profit Margin (Annual)-220.22%
Month-to-Date Return10.92%
Cash Flow / Share (TTM)$-0.46
EBITD / Share (Annual)$-1.64
Operating Margin (Annual)-363.28%
LT Debt / Equity (Annual)0.86x
ROI (5Y Avg)-59.99%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.16
P/TBV (Quarterly)8.71x
P/B Ratio (Annual)3.52x
Inventory Turnover (TTM)1.89x
Pretax Margin (TTM)-341.38%
Book Value / Share (Annual)$2.38
Price vs S&P 500 (13W)-21.60%
Beta1.45x
P/FCF (Annual)0.84x
Revenue / Share (TTM)$0.45
ROE (TTM)339.23%
52-Week Low$0.72
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.14
4.14
4.14
4.14
Industry Peers — Agricultural Chemicals(9)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
EVGNEVOGENE LTD. | 2.61x | -53.54% | 49.04% | — | $0.80 |
NTRNutrien Ltd. Common Shares | 1.31x | 3.52% | 31.05% | 42.06% | $74.53 |
CFCF Industries Holding, Inc. | 2.65x | 19.34% | 38.45% | 43.50% | $124.71 |
MOSThe Mosaic Company | 0.63x | 8.36% | 15.78% | -0.61% | $24.73 |
SMGThe Scotts Miracle-Gro Company | 1.08x | -5.85% | 31.47% | -18.33% | $62.44 |
UANCVR Partners, LP | 2.16x | 15.36% | 40.47% | — | $126.54 |
CBUSCibus, Inc. Class A Common Stock | 29.93x | -14.62% | 100.00% | — | $1.43 |
AVDAmerican Vanguard Corporation | 0.14x | -5.88% | 28.65% | — | $2.61 |
SNESSenesTech, Inc. Common Stock | 3.87x | 19.60% | 62.49% | — | $1.62 |
NXTSNexentis Technologies Inc. Common Stock | 14.01x | 18.94% | 66.20% | — | $3.97 |
About
Evogene Ltd is a computational biology company that uses its Computational Predictive Biology platform to discover and develop life-science products based on microbes, small molecules, and genetic elements. The company operates across three sectors—agriculture, human health, and industrial applications—through a portfolio of subsidiaries developing agricultural biologicals, seed traits, microbiome therapeutics, and specialty chemicals. Revenue is generated primarily from the agriculture segment.